US Orphan status for Almac’s ovarian cancer drug
PharmaTimes Media Ltd | July 05, 2017
In big news for Northern Ireland-headquartered drug discovery group Almac, US regulators have awarded orphan drug status to the firm’s experimental therapy for ovarian cancer. ALM201 is a first-in-class therapeutic peptide developed to mimic some of the properties of the naturally occurring protein FKBPL, known to have an effect on a number of important tumour biology processes, including cancer stem cells and angiogenesis.